Ann: December 2022 Preclinical & Clinical Programs Update, page-13

@BillyHill I believe this is the value-add work the team is doing, while waiting for the new formulation to be finalised (or something like that). Think it was mentioned at the AGM. I think the new formulation will be used for the breast cancer study that has been designed and announced to market. So it is an interim activity while we wait for that activity to occur pre-breast cancer (cardio protection) study, and while we also wait for trial sites to come up and recruiting to begin for the AML study. Soon we will have these big needle mover trials underway and hopefully results in 2023. Will be make or break with the two pivotal trials (in my mind) likely to start this year. As always with RAC expecting good unexpected news also.